Public Sector Pension Investment Board Has $53.09 Million Holdings in Johnson & Johnson $JNJ

Public Sector Pension Investment Board lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 49.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 286,327 shares of the company’s stock after selling 279,004 shares during the quarter. Public Sector Pension Investment Board’s holdings in Johnson & Johnson were worth $53,091,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Clayton Financial Group LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth about $28,000. Evolution Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson in the second quarter valued at about $27,000. Semmax Financial Advisors Inc. raised its holdings in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares in the last quarter. Compass Financial Services Inc boosted its position in Johnson & Johnson by 707.1% during the third quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock valued at $42,000 after purchasing an additional 198 shares during the last quarter. Finally, Signature Resources Capital Management LLC grew its stake in Johnson & Johnson by 262.9% in the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after purchasing an additional 184 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $244.54 on Friday. The stock has a market cap of $589.17 billion, a PE ratio of 22.13, a P/E/G ratio of 2.34 and a beta of 0.35. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm has a 50-day moving average of $216.42 and a 200-day moving average of $195.85. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $246.35.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The business had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. HSBC upped their price objective on Johnson & Johnson from $240.00 to $265.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Citigroup upped their price target on shares of Johnson & Johnson from $232.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Sanford C. Bernstein lifted their price objective on shares of Johnson & Johnson from $208.00 to $225.00 and gave the company a “market perform” rating in a research report on Friday, January 23rd. Argus upped their target price on shares of Johnson & Johnson from $210.00 to $240.00 in a report on Friday, January 23rd. Finally, Leerink Partners lifted their price target on Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $233.73.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.